Sai Life Sciences Reports Q2 Results, Key Leadership Appointments, and Equity Allotment
Sai Life Sciences Ltd · Others (Uncategorized) · 06 Nov 2026, 4:39 am
Sai Life Sciences Reports Q2 Results, Key Leadership Appointments, and Equity Allotment For Q2 ended 30th Sep'26, Sai Life Sciences posted consolidated revenue from operations of ₹6,585.85 mn, up 22.5% YoY, and profit after tax of ₹983.17 mn versus ₹838.44 mn in Q2'25. Basic EPS stood at ₹4.63. The Board approved the appointments of Sidhartha Das as SVP & Head HR, Vijay Kumar Suthari as VP Head Quality & Regulatory Affairs, and Sriram Gopalakrishnan as SVP Corporate Communications. Additionally, the company allotted 1,08,005 equity shares under its ESOP and MESOP schemes, expanding paid-up capital to ₹21,25,80,721.
Original exchange filing (PDF)
More announcements from Sai Life Sciences Ltd
- Upgradation in the Credit Rating by India Rating & Research Pvt. Ltd. · 14 Nov 2026
- Transcripts of Earnings call organized on 06th November 2026 · 12 Nov 2026
- Monitoring Agency Report for the Quarter ended 30th September 2026 · 12 Nov 2026
- Audio Recording of Earnings call for Q-2 FY 2026-27 · 06 Nov 2026
- Investor Presentation on Q-2 FY 2026-27 Financial Results · 06 Nov 2026
- Press Release on Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September 2026. · 06 Nov 2026
- Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. · 06 Nov 2026
- Change In Management - Appointment of SMPs · 06 Nov 2026
